{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:53:08Z","timestamp":1790707988019,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.purol.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T11:53:44Z","timestamp":1422964424000},"page":"461-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hyperactivit\u00e9 v\u00e9sicale idiopathique et BOTOX\u00ae\u00a0: revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"25","author":[{"given":"X.","family":"Gam\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ballanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chartier-Kastler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Deffieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Haab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-F.","family":"Hermieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Le Normand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saussine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2015.01.006_bib0005","first-page":"1103","article-title":"[Terminology of lower urinary tract dysfunction: French adaptation of the terminology of the International Continence Society]","volume":"14","author":"Haab","year":"2004","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"Reviewing the ICS 2002\u00a0terminology report: the ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2015.01.006_bib0015","author":"Publications"},{"issue":"Suppl","key":"10.1016\/j.purol.2015.01.006_bib0020","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.purol.2015.01.006_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.eururo.2011.01.031","article-title":"The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study","volume":"59","author":"Vaughan","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-008-0600-9","article-title":"Persistence of antimuscarinic drug use","volume":"65","author":"Brostr\u00f8m","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.purol.2015.01.006_bib0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11597970-000000000-00000","article-title":"Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies","volume":"29","author":"Sand","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.purol.2015.01.006_bib0050","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2015.01.006_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0060","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0065","first-page":"260","article-title":"Refractory urge urinary incontinence and botulinum A injection: the methods of the RUBI trial","volume":"6","author":"Brubaker","year":"2006","journal-title":"J Appl Res"},{"key":"10.1016\/j.purol.2015.01.006_bib0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0075","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","article-title":"Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2015.01.006_bib0085","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100\u00a0versus 150\u00a0units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2015.01.006_bib0095","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2015.01.006_bib0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0110","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00192-011-1655-1","article-title":"Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB","volume":"23","author":"Brubaker","year":"2012","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.purol.2015.01.006_bib0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100U vs 200U botox in the treatment of idiopathic overactive bladder","volume":"3","author":"Altaweel","year":"2011","journal-title":"Urol Ann"},{"key":"10.1016\/j.purol.2015.01.006_bib0120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","article-title":"The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial","volume":"65","author":"Dowson","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.purol.2015.01.006_bib0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240\u00a0women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0135","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised double-blind placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.2003.04312.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"92","author":"Harper","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2015.01.006_bib0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0155","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0160","first-page":"CD005493","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","volume":"12","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2015.01.006_bib0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (BOTOX\u00ae) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.urology.2006.05.054","article-title":"Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?","volume":"68","author":"Kuo","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.purol.2015.01.006_bib0180","series-title":"Prescribing information","author":"BOTOX\u00ae","year":"2013"},{"key":"10.1016\/j.purol.2015.01.006_bib0185","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2015.01.006_bib0190","first-page":"3291","article-title":"Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection","volume":"13","author":"Lucioni","year":"2006","journal-title":"Can J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0195","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0200","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.purol.2009.02.001","article-title":"Le point sur les traitements de seconde ligne de l\u2019hyperactivit\u00e9 v\u00e9sicale idiopathique","volume":"19","author":"Chartier-Kastler","year":"2009","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0205","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0210","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2015.01.006_bib0215","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3\u00a0efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0220","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0225","unstructured":"European Association of Urology, online guidelines http:\/\/www.uroweb.org, update 2013: urinary incontinence: Surgical interventions for refractory DO."},{"key":"10.1016\/j.purol.2015.01.006_bib0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2005.01.036","article-title":"Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction","volume":"66","author":"Schulte-Baukloh","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.purol.2015.01.006_bib0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11255-011-9979-9","article-title":"Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity","volume":"44","author":"Kanagarajah","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.purol.2015.01.006_bib0240","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2008.11.110","article-title":"What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection","volume":"181","author":"Khan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0245","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.urology.2009.05.097","article-title":"Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity","volume":"75","author":"Sahai","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.purol.2015.01.006_bib0250","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2006.07.022","article-title":"Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results","volume":"50","author":"Patel","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2015.01.006_bib0260","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","article-title":"Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure","volume":"15","author":"Schulte-Baukloh","year":"2008","journal-title":"Int J Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871500007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871500007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:26:19Z","timestamp":1761114379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670871500007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S116670871500007X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2015.01.006","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperactivit\u00e9 v\u00e9sicale idiopathique et BOTOX\u00ae\u00a0: revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}